Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Plc Regulatory News (ZTF)

Share Price Information for Zotefoams Plc (ZTF)

Share Price is delayed by 15 minutes
Get Live Data
424.00    -15.00 (-3.42%)
Bid:
426.00
Ask:
430.00
Spread: 4.00 (0.939%)
Market Cap: £208.53m
ZTF Live PriceLast checked at - London Stock Exchange

Intraday Zotefoams Plc Share Chart

Acquires Stake

9 Jul 2008 09:11

RNS Number : 6530Y
Zotefoams PLC
09 July 2008
 



9 July 2008

Zotefoams plc

Investment in Unique Foam Technology

Zotefoams plc announces today that, effective July 8 2008, it has acquired a 30% stake in a subsidiary set up specifically by Trexel Inc. to exploit and further develop microcellular foam technology for extrusion. The new subsidiary, MuCell Extrusion LLC, will be owned 70% by Trexel Inc., a US-based company specialising in microcellular foaming of thermoplastic polymers by injection moulding and extrusion.

Trexel has established a global proprietary position with patents and know how under the MuCell® brand in microcellular foaming using supercritical nitrogen and CO2. Zotefoams is the world market leader in high-performance, cross-linked foams using pure nitrogen. Trexel licensees in the extrusion field apply the MuCell Process to a wide range of applications in electronics, sealing systems, packaging, and wire and cable production.

Zotefoams will install a commercial-scale MuCell extrusion line in its Croydon factory to facilitate scale up of the MuCell Extrusion technology for third party licensees. Zotefoams will also become a licensee to develop microcellular foams for certain advanced materials.

Zotefoams' initial investment in MuCell Extrusion LLC is US$3 million, which will be met from existing cash resources, and includes an option to purchase 100% ownership. The earliest this option can be exercised is July 2010 but, depending on certain performance conditions, may be exercised as late as June 2011. 

MuCell Extrusion LLC is a newly created company with intellectual property rights, minimal tangible assets and US$0.5 million of cash. The business previously traded as part of Trexel Inc., a privately held company, and in the year ending 30 June 2007 it is estimated that it had a profit before tax of US$0.6 million. The acquisition of a 30% stake is expected to have a marginal impact on Zotefoams' earnings per share in 2008 but it is anticipated that it will generate a growing income from its licensing portfolio in addition to allowing Zotefoams to develop its own microcellular foams for certain advanced materials as a licensee.

Commenting on the deal David Stirling, Managing Director of Zotefoams plc, said: "I am delighted that we have concluded a deal to bring the MuCell technology into Zotefoams. The benefits of a clean and consistent foaming technology are well known to Zotefoams' customers. The structure of this deal allows Zotefoams plc to operate under the MuCell license to offer thin roll foams of a high consistency with no chemical agents which has the potential to open significant new markets for us. Participation in the MuCell extrusion venture allows us to broaden our markets and to assist in the profitable growth of MuCell Extrusion LLC by bringing our own industry knowledge and contacts to the business."

Enquiries:

Zotefoams plc
0208-664-1600
David Stirling, Managing Director
 
Clifford Hurst, Finance Director
 

 

Financial Dynamics Limited
0207-831-3113
Ben Brewerton
 

 

About Zotefoams plc 

Zotefoams plc (LSE - ZTF) is the world's leading producer of light weight, cross-linked, closed-cell block foams. These pure, consistent foams are manufactured using a unique environmentally friendly nitrogen expansion technology. Zotefoams was the first to develop cross-linked polyolefin foams and is increasingly using its production technology to manufacture foamed materials based on high performance polymers. Based in CroydonUK, Zotefoams also manufactures in KentuckyUSA and markets its products worldwide through a global sales network. www.zotefoams.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCGGGGNRLVGRZG
Date   Source Headline
27th May 20264:06 pmRNSNotification of Transactions of Directors/PDMRs
27th May 20264:00 pmRNSResult of the 2026 Annual General Meeting
27th May 20267:00 amRNSTrading Update
12th May 20267:00 amRNSInvestor Presentation via Investor Meet Company
11th May 20267:00 amRNSNotification of Transactions of Directors/PDMRs
7th May 20267:00 amRNSIssue of Equity
30th Apr 20261:00 pmRNSFinal Dividend Payment Date
27th Apr 20267:00 amRNS2025 Annual Report and Notice of the 2026 AGM
15th Apr 20269:24 amRNSNotification of Transactions of Directors/PDMRs
31st Mar 20266:06 pmRNSHolding(s) in Company
25th Mar 20269:35 amRNSNotification Of Transactions Of Directors/PDMRs
17th Mar 20267:00 amRNSPreliminary Results
17th Mar 20267:00 amRNSPreliminary Results
16th Mar 20261:24 pmRNSNotification Of Transactions Of Directors/PDMRs
16th Mar 20261:24 pmRNSNotification Of Transactions Of Directors/PDMRs
11th Mar 20267:00 amRNSPreliminary results presentation
11th Mar 20267:00 amRNSPreliminary results presentation
13th Feb 20267:00 amRNSNotification Of Transactions Of Directors/PDMRs
27th Jan 20267:00 amRNSChange of Registered Office Address
22nd Jan 20267:00 amRNSTrading Update
15th Jan 20269:57 amRNSNotification Of Transactions Of Directors/PDMRs
15th Dec 20257:00 amRNSNotification Of Transactions Of Directors/PDMRs
18th Nov 202512:39 pmRNSAcquisition of Overseas Konstellation Company S.A.
12th Nov 20254:12 pmRNSNotification Of Transactions Of Directors/PDMRs
4th Nov 20257:00 amRNSTrading Update
24th Oct 20257:00 amRNSNon-Executive Directorate Changes
14th Oct 20252:54 pmRNSNotification Of Transactions Of Directors/PDMRs
9th Oct 20257:00 amRNSNotification Of Transactions Of Directors/PDMRs
30th Sep 20254:25 pmRNSNOTIFICATION OF TRANSACTIONS OF DIRECTORS/PDMRs
22nd Sep 20252:33 pmRNSGroup CFO succession
12th Sep 20255:11 pmRNSNotification Of Transactions Of Directors/PDMR
28th Aug 20257:00 amRNS-RInnovation Initiatives and Executive Appointment
19th Aug 20252:16 pmRNSHolding(s) in Company
14th Aug 20256:19 pmRNSHolding(s) in Company
12th Aug 20252:57 pmRNSNotification Of Transactions Of Directors/PDMR
8th Aug 20257:00 amRNSHolding(s) in Company
7th Aug 202512:14 pmRNSHolding(s) in Company
5th Aug 20257:01 amRNSJoint Venture Agreement and Executive Appointment
5th Aug 20257:00 amRNSInterim Results
29th Jul 202511:01 amRNSInvestor Presentation via Investor Meet Company
14th Jul 20252:51 pmRNSNotification Of Transactions Of Directors/PDMRs
12th Jun 20252:41 pmRNSNotification of Transactions of Directors/PDMRs
10th Jun 20254:13 pmRNSNotification Of Transactions Of Directors/PDMRs
22nd May 202512:30 pmRNSResult of the 2025 Annual General Meeting
22nd May 20257:00 amRNSTrading Update
13th May 202512:05 pmRNSNotification Of Transactions Of Directors/PDMRs
1st May 20257:00 amRNSNotification Of Transactions Of Directors/PDMRs
30th Apr 20257:00 amRNSGroup CFO succession
24th Apr 20257:00 amRNSNotification Of Transactions Of Directors/PDMRs
22nd Apr 20257:00 amRNS2024 Annual Report & Notice of 2025 AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.